In a recent Reuters article, IPOX® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.

IPOX® Analyst Lukas Muehlbauer comments on Andersen Group's $1.75 billion IPO in a recent Reuters article. Muehlbauer describes the listing as a "resurrection story" for the brand formerly linked to Arthur Andersen. He notes that the decision to list now suggests management is prioritizing immediate capital access over 2026 volatility, while strategically aligning the deal with strong financial results from tax-extension seasonality.

A recent Bloomberg article examines the contraction of Canada’s public markets, where delistings are outpacing IPOs. IPOX® CEO Josef Schuster weighs in on the lack of domestic momentum, noting that Canadian firms are growing but often listing elsewhere. He emphasizes the need for a "strong first deal" to act as a catalyst and reignite the Canadian IPO market for the coming year.

AI takes the lead as Anthropic preps for a potential 2026 IPO and Baidu’s Kunlunxin eyes a Hong Kong listing. IPOX® Associate Lukas Muehlbauer comments on Wealthfront’s $2.05 billion target amid mixed sentiment. Elsewhere, Unilever’s ice cream unit advances spin-off plans, Barrick Gold explores a North American IPO, and Morgan Stanley predicts a dealmaking surge, even as travel unicorn Klook delays its U.S. debut.

In Kiplinger, David Milstead examines the surging U.S. IPO market, cautioning against risks from heavy AI and cryptocurrency concentration. He suggests navigating this volatility through diversified ETFs rather than individual stocks. Milstead highlights the First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index. Up 39.3% in 2025, FPX captures major recent listings, offering investors broad exposure with reduced volatility compared to potentially riskier alternatives in this heated market.

Wealthfront targets a $2.05 billion valuation in its upcoming U.S. IPO. In recent Reuters coverage, IPOX® Associate Lukas Muehlbauer discusses the firm's strategic positioning at the "intersection of artificial intelligence and fintech." Muehlbauer highlights that while investor demand for new listings remains high, market sentiment is still susceptible to volatility. Read the full post for insights on Wealthfront’s plans and the current IPO market landscape.

Bill Ackman targets a massive $5 billion IPO for a new closed-end fund, while sports tech firm Enhanced agrees to a $1.2 billion SPAC merger. IPOX® CEO Josef Schuster notes the SPAC model’s enduring relevance following the deal. Elsewhere, the UK introduces stamp duty relief to revitalize London listings, and Hong Kong sees a flurry of activity with Syngenta’s potential pivot and new filings from Suzhou Novosense and Muyuan Foods.

Sports technology firm Enhanced plans to go public via a $1.2 billion merger with A Paradise Acquisition Corp, highlighting a resurgence in the blank-check market. IPOX CEO Josef Schuster noted that "SPACs are here to stay," driven by the success of innovative companies from the previous cycle. Co-founded by Christian Angermayer, the company plans to host sporting events where performance-enhancing drugs are allowed. The company expects to list on the Nasdaq under the ticker "ENHA" in the first half of 2026.

In a new Bloomberg feature, IPOX® Schuster Founder Josef Schuster discusses the impact of the recent crypto crash on the US IPO market. With returns from new listings waning, Schuster notes that crypto is currently the "least favored sector" due to sustained investor losses. He suggests that while upcoming issuers may not need to postpone their debuts, they will likely face pressure to adjust pricing expectations downward. Read more about the challenging landscape for digital asset public offerings.

Asia-Pacific dominates this week, led by SBI Shinsei Bank’s potential $2.4 billion Tokyo relisting and CK Hutchison’s plan for a $2 billion AS Watson float. Singapore sees UltraGreen.ai targeting $400 million, while the U.S. pipeline heats up with crypto giant Kraken filing for a 2026 debut and Grayscale seeking a NYSE spot. MENA activity is strong with Saudi Global Ports eyeing $1 billion. Meanwhile, Uzbekistan’s sovereign fund prepares for a historic London listing, signaling renewed global momentum across diverse sectors.

On November 20, Central Bancompany shares climbed in their Nasdaq debut, securing a $5.26 billion valuation after raising $373 million. The listing continues a strong year for financial IPOs. IPOX® CEO Josef Schuster commented on investor confidence, stating, “The bank's successful trajectory fits well with investors looking for exposure to banks operating in markets with strong economic growth.” The Missouri-based lender manages $19.2 billion in assets.

Global IPO activity intensifies with major U.S. filings including Blackstone-backed Copeland ($4.75B revenue), Grayscale ($35B AUM), and SoftBank-backed Klook ($417M revenue). Asia-Pacific markets see SBI Shinsei Bank's $2.1 billion Tokyo offering and Kbank's third KOSPI attempt. European developments feature BASF's 2027 Frankfurt listing plans and Bending Spoons eyeing a 2026 U.S. IPO at $11 billion valuation. IPOX analysts highlighted travel sector opportunities and cautioned about market volatility.

Reuters highlighted Klook’s strong 2024 performance, revealing a 24% rise in revenue in its U.S. IPO filing. The SoftBank-backed platform seeks to list on the New York Stock Exchange as global travel rebounds. IPOX® Vice President Kat Liu noted Klook’s advantage in the underpenetrated travel experiences market while cautioning about thinner margins and fragmented supply. Goldman Sachs leads the offering’s underwriting team.

This week's IPO activity featured significant U.S. SPAC deals, including Dubai hookah maker AIR's $1.75 billion Nasdaq listing and Xanadu Quantum's $3.6 billion merger. Aeromexico successfully debuted on NYSE at a $2.8 billion valuation. International markets saw Malaysia's Sunway Healthcare planning a $1 billion IPO, while Germany's Mobile.de attracted interest ahead of a potential €10 billion listing. IPOX analysts highlighted SPAC revival momentum and MENA market valuation challenges.